Accessibility Menu
Eton Pharmaceuticals logo

Eton Pharmaceuticals(NASDAQ) ETON

Market Cap$1.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+842%
5 Year+1,232%
1 Year+252%
1 Month+53%
$58.86
+44.27%
+18.06Today
Eton Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 58.862026-08-14
Eton Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+31.97%USD 44.602026-08-07
1 month+52.88%USD 38.502026-07-15
3 month+94.51%USD 30.262026-05-15
Year to date+248.08%USD 16.912025-12-31
1 year+252.46%USD 16.702025-08-14
3 year+1,141.77%USD 4.742023-08-15
5 year+1,231.67%USD 4.422021-08-13
Since inception+841.76%USD 6.252018-11-13

Eton Pharmaceuticals Financials at a Glance

Market Cap

$1.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$105.60M

Net Income (TTM)

$12.69M

EPS (TTM)

$0.38

P/E Ratio

155.63

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$58.86

Volume

1,320.943

Open

$54.93

Previous Close

$58.86

Daily Range

$53.01 - $59.79

52-Week Range

$14.27 - $59.79

Estimated Earnings Date

Nov 5, 2026

ETON News

Scientists study strands of DNA

Why Eton Pharmaceuticals Is Top of the Class Today

Rich SmithAug 14, 2026
Foolcom-Featured.png

Eton (ETON) Q2 Revenue Jumps 108%

Motley Fool Markets TeamAug 7, 2025

ETON: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eton Pharmaceuticals

Eton helps patients with rare diseases get specialized medicines. They make treatments easier to take, especially for children. The company sells drugs for conditions affecting small groups.

Medicines for Rare Needs

  • Endocrinology Treatments: Specialized medicines including INCRELEX for growth deficiency and ALKINDI SPRINKLE for adrenal insufficiency, a condition where the body does not make enough cortisol.
  • Metabolic Disease Products: Portfolio featuring treatments for rare inherited conditions, such as GALZIN for Wilson disease and PKU GOLIKE, a medical formula for phenylketonuria management.
  • Generic Rare Medicines: Approved versions of existing drugs like Carglumic Acid for treating high ammonia levels and Betaine Anhydrous for inherited chemical imbalances.

Recent Deals and New Rights

  • Acquired U.S. rights to PKU GOLIKE in March 2024 to provide specialized nutrition for patients with phenylketonuria.
  • Licensed Amglidia from AMMTeK in November 2024 to develop a liquid treatment for neonatal diabetes in the United States.
  • Expanded metabolic and endocrinology portfolios in December 2024 through the acquisition of INCRELEX and GALZIN.
  • Acquired the treatment Nitisinone in October 2023 for patients with an ultra-rare condition called tyrosinemia type 1.

What Makes Eton Different

The company utilizes the 505(b)(2) regulatory pathway, which is a process that allows for faster drug approval by using data from existing medicines. They also manage the Eton Cares program to help patients navigate insurance and access high-touch medical support.

The Latest Numbers

  • Revenue was $21.3 million in Q4 2025, up 82.7% from Q4 2024.
  • Operating income reached $2.5 million in Q4 2025, up 291.7% from Q4 2024 as the company turned positive.
  • Net income hit $1.5 million in Q4 2025, up 348% from a loss in Q4 2024.
  • Free cash flow reached negative $22.1 million in Q4 2025, worsened from negative $777,000 in Q4 2024.

Evolution into Commercial Sales

Eton has transitioned into a profitable pharmaceutical company with a diverse portfolio of eight commercial rare disease products. Its strategy relies on acquiring under-appreciated assets and using efficient development paths to serve small patient populations.

AI Generated • May 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

44

CEO

Sean E. Brynjelsen, MBA

Website

www.etonpharma.com

Headquarters

Deer Park, IL 60010-7278, US

ETON Financials

Key Financial Metrics (TTM)

Gross Margin

57.87%

Operating Margin

15.44%

Net Income Margin

12.02%

Return on Equity

40.13%

Return on Capital

0.13%

Return on Assets

10.96%

Earnings Yield

0.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

27.39M

Volume

1.32K

Avg. Volume

502.23K

Financials (TTM)

Gross Profit

$61.10M

Operating Income

$16.31M

EBITDA

$18.56M

Operating Cash Flow

$15.14M

Capital Expenditure

-$403.00K

Free Cash Flow

$14.73M

Cash & ST Invst.

$26.85M

Total Debt

$9.91M

Eton Pharmaceuticals Performance Analysis

Eton Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 21,251,000-2.7%
20232023-12-31USD 31,642,00048.9%
20242024-12-31USD 39,011,00023.3%
20252025-12-31USD 79,950,000104.9%
Eton Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3018.7%
Q42025-12-31-5.2%
Q12026-03-3114.0%
Q22026-06-3054.9%
Eton Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.36362.4%
20232023-12-31USD -0.04-89.8%
20242024-12-31USD -0.15304.4%
20252025-12-31USD -0.1715.9%
Eton Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3027.2%
Q42025-12-31178.0%
Q12026-03-31-8.4%
Q22026-06-30600.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$37.59M

+98.6%

Gross Profit

$25.41M

+113.1%

Gross Margin

67.61%

N/A

Market Cap

$1.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$36.64M

N/A

Employees

44

N/A

Net Income

$11.58M

+547.9%

EBITDA

$12.79M

+4148.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$26.85M

+5.8%

Total Debt

$9.91M

-67.7%

Accounts Receivable

$24.89M

+72.2%

Inventory

$10.14M

-57.4%

Long Term Debt

$2.17M

-92.2%

Short Term Debt

$8.83M

+218.7%

Return on Assets

10.96%

N/A

Return on Invested Capital

23.07%

N/A

Free Cash Flow

$7.26M

-8.8%

Operating Cash Flow

$7.26M

-8.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OMEROmeros Corporation
$17.19-0.92%
LXRXLexicon Pharmaceuticals, Inc.
$2.32-0.85%
RAPTRAPT Therapeutics, Inc.
$58.01+0.00%
MNPRMonopar Therapeutics Inc.
$113.04+2.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$144.95-0.00%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$40.28+0.00%
SPCXSpace Exploration Technologies
$140.00-0.01%
NOKNokia
$10.76+0.02%

Questions About ETON

What is the current price of Eton Pharmaceuticals?

Eton Pharmaceuticals is trading at $58.86 per share.

What is the 52-week range for Eton Pharmaceuticals?

Over the past 52 weeks, Eton Pharmaceuticals has traded between $14.27 and $59.79.

How much debt does Eton Pharmaceuticals have?

As of the most recent reporting period, Eton Pharmaceuticals reported total debt of $29.23M.

How much cash does Eton Pharmaceuticals have on hand?

Eton Pharmaceuticals reported $26.85M in cash and cash equivalents in its most recent financial results.

What is Eton Pharmaceuticals’s dividend yield?

Eton Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services